Precise Therapy for Patients With AML: Experts Discuss Clinical Challenges and Future Directions

In this online program faculty experts explore the latest developments in individualizing therapy for patients with AML through the use of recently approved targeted agents novel immunotherapies and investigational agents. 

Share

Program Content

Activities

Biomarkers in AML
Biological Markers for Predicting Outcomes in Acute Myeloid Leukemia
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: May 31, 2019

Expires: May 29, 2020

Immunotherapy in AML
Targeting Antigens in AML: New Advances in Antibody–Drug Conjugates and Other Antibody-Based Therapies
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: May 31, 2019

Expires: May 29, 2020

FLT3- and IDH1/2-Mutant AML
Available and Emerging Treatment Options in IDH-Mutant and FLT3-Mutant AML
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: May 31, 2019

Expires: May 29, 2020

Investigational AML Agents
Future Directions for Novel Therapeutic Agents in AML
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: May 31, 2019

Expires: May 29, 2020

Treating ND AML
Overcoming Treatment Challenges in Patients With Newly Diagnosed AML
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: May 31, 2019

Expires: May 29, 2020

Activities

Precise Therapy for AML
Precise Therapy for Patients With AML: Experts Discuss Clinical Challenges and Future Directions
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: July 10, 2019

Expires: July 08, 2020

Faculty

cover img faculity

Farhad Ravandi, MD

Professor of Medicine
Department of Leukemia
University of Texas M. D. Anderson Cancer Center
Houston, Texas

cover img faculity

Ellen K. Ritchie, MD

Associate Professor
Division of Hematology and Oncology
Department of Medicine
Weill Cornell Medical College
New York, New York

cover img faculity

Eytan M. Stein, MD

Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

ProCE Banner

Supporters

Supported by educational grants from

Agios Pharmaceuticals

Boston Biomedical

Celgene TEXT Only

Daiichi Sankyo, Inc.